In April 2026, Regeneron Pharmaceuticals co-founder and Chief Scientific Officer George Yancopoulos traveled to Washington, D.C., to discuss the company’s newly approved gene therapy Otarmeni for OTOF-related hearing loss, which Regeneron will provide free to eligible U.S. patients. The visit underscored a defining moment for the biotech veteran, who has consistently championed an internal, biology-driven drug discovery model amidst an industry increasingly defined by merger activity, crowded target spaces, and artificial intelligence hype. Over a four-decade career, Yancopoulos has accumulated approximately 1,000 patents and spearheaded the development of multiple blockbuster therapies. Yet, he remains openly critical of contemporary pharmaceutical trends. At recent industry forums, he condemned companies chasing validated targets merely to replicate market successes, noting that concentrated investment in narrow pathways risks sidelining higher-risk, higher-reward biological exploration. Data supports his concern: the proportion of R&D portfolios focused on highly contested targets has surged from 16 percent in 2000 to 68 percent by 2020, compressing development cycles and intensifying competition. Regeneron, holding over $18 billion in cash, could easily pivot toward acquisition-driven growth. Instead, Yancopoulos has directed capital toward internal research, sustaining a pipeline of roughly 60 programs across oncology, neurodegeneration, and immunology. This commitment recently materialized in the company’s obesity drug strategy. Rather than duplicating the proliferating GLP-1 candidates, Regeneron leveraged its human genetics database of 645,000 individuals to identify GPR75 loss-of-function variants linked to a 54 percent reduction in obesity risk. The finding is now being translated into antibody and RNA interference candidates, exemplifying the firm’s foundational approach: derive targets from human genetics, validate through experimental biology, and advance only with mechanistic certainty. The rise of artificial intelligence in drug discovery has drawn comparable scrutiny. While computational tools have accelerated molecular modeling, Yancopoulos maintains that algorithmic efficiency cannot substitute for hypothesis-driven science. Regeneron employs machine learning primarily to parse its multi-million-sample genetic and health records, enhancing data connectivity rather than dictating research direction. In Yancopoulos’s view, AI serves as an analytical enhancer; the critical judgments regarding target validity and clinical translatability remain grounded in human genetics, animal models, and clinical trial design. This methodology faces mounting commercial pressure. Flagship products such as Eylea and Dupixent confront biosimilar competition and impending patent expiries, demanding a steady flow of next-generation therapies. Yancopoulos acknowledges the necessity of revenue generation to fund high-risk exploration, but refuses to compromise scientific rigor for short-term market alignment. His stance challenges the prevailing industry paradigm, positioning Regeneron’s biology-first, internally driven model as a deliberate counterweight to consolidation and algorithmic optimism. As the pharmaceutical sector navigates AI integration and therapeutic redundancy, Yancopoulos’s leadership reinforces a foundational conviction: sustainable innovation requires deep mechanistic understanding, not accelerated replication. Whether this disciplined, genetics-led strategy can sustain Regeneron’s competitive edge through upcoming patent cliffs and evolving market dynamics remains to be seen. What is certain is that the company will prioritize biological truth over industry convention.